More chemotherapy, better surgery, no survival gain
In the long effort to refine how medicine approaches one of oncology's most formidable diseases, a French-led clinical trial has quietly closed a door that many hoped would open. The CHRONO trial, presented at ASCO this spring, asked whether giving women with advanced ovarian cancer three additional rounds of chemotherapy before surgery would extend their time free of disease — and after nearly four years of follow-up across 209 patients, the answer was no. The finding does not diminish the search for better treatment sequences, but it redirects it: the question is no longer simply how much chemotherapy, but for whom, and why.
- A trial built on sound biological logic — more chemotherapy, smaller tumors, cleaner surgery — failed to deliver the survival benefit it was designed to detect.
- The delayed surgery group achieved complete tumor removal in 90% of cases versus 83.2% in the standard group, yet this surgical advantage evaporated when measured against time without disease progression.
- Women who waited longer for surgery faced more than twice the rate of severe surgical complications, and grade 3–4 adverse events nearly doubled, making the extended approach a harder road for no measurable gain.
- The trial's own assumptions undermined its power: the control group survived nearly twice as long as predicted, leaving researchers unable to confirm or rule out a modest benefit in the delayed arm.
- The field is now pointed toward tumor biology and chemosensitivity as the next frontier — the hope that a subgroup exists for whom extended neoadjuvant chemotherapy genuinely helps, if only they can be identified.
A clinical trial testing whether ovarian cancer patients should wait longer before surgery has returned an unexpected verdict: the extra wait does not help. The CHRONO trial, presented this spring at the American Society of Clinical Oncology annual meeting, enrolled 209 women with advanced high-grade epithelial ovarian cancer and divided them into two groups — one proceeding to surgery after three chemotherapy cycles, the other receiving three additional rounds first. After nearly four years of follow-up, the survival difference between them was negligible.
The trial's primary measure was disease-free survival. Women in the delayed surgery group went a median of 23.4 months without disease progression; those in the standard group, 20.2 months. The gap failed to reach statistical significance. The reasoning behind extended chemotherapy had been compelling — more drug exposure might shrink tumors further and improve surgical outcomes. And indeed it did: complete tumor removal was achieved in 90% of the delayed group versus 83.2% in the standard group. Yet this surgical advantage did not translate into longer survival, and time to subsequent treatment was similarly close between the arms.
The cost of waiting was measurable. Severe adverse events within 30 days of surgery occurred in 11% of the delayed group versus 5% of those who had earlier surgery, and serious surgical complications were more than twice as common. Neither group experienced a postoperative death. Quality of life assessments showed no significant differences between the arms, though numerical trends in social functioning and sleep favored the delayed group without reaching significance.
A critical limitation tempers the conclusions: the trial assumed the standard group would achieve a median disease-free survival of roughly 10 months. Instead, they reached 20.2 months — nearly double the expectation. This better-than-anticipated outcome in the control arm likely left the study underpowered to detect a real difference, even if one existed. The researchers now call for future studies stratifying patients by tumor biology and chemosensitivity, seeking the subgroup, if any, for whom extended neoadjuvant chemotherapy genuinely earns its risks. For most women with advanced ovarian cancer today, the evidence continues to favor surgery after three cycles.
A large clinical trial testing whether ovarian cancer patients should wait longer before surgery has delivered an unexpected answer: the extra wait does not help. The CHRONO trial, presented this spring at the American Society of Clinical Oncology annual meeting, randomized 209 women with advanced high-grade epithelial ovarian cancer into two groups. One group went to surgery after three rounds of chemotherapy. The other received three additional rounds before the operating room. After nearly four years of follow-up, the difference in survival between them was negligible.
The trial's primary measure was disease-free survival—the time before cancer returns or worsens. Women who waited for six chemotherapy cycles before surgery lived a median of 23.4 months without disease progression. Those who had surgery after three cycles lived 20.2 months. The gap was not statistically significant. The researchers, led by Jean-Marc Classe of the Institut de Cancérologie de l'Ouest in France, had powered the study to detect a meaningful improvement with the longer approach. They did not find one.
The logic behind testing extended chemotherapy was sound. More drug exposure might shrink tumors further, making them easier to remove completely. Indeed, the delayed surgery group did achieve complete tumor removal in 90 percent of cases, compared to 83.2 percent in the standard group. Yet this surgical advantage did not translate into longer survival. Time to subsequent treatment—another measure of how long women remained stable—was also similar: 26.3 months versus 24.8 months. Overall survival data remained immature at the time of analysis, with median survival around 60 months in the delayed group and 50.5 months in the standard group, but again without statistical significance.
The trade-off for the extra chemotherapy was measurable toxicity. Grade 3 or 4 adverse events within 30 days of surgery occurred in 11 percent of women who waited versus 5 percent of those who had earlier surgery. Surgery-related severe complications were more than twice as common in the delayed group. Chemotherapy-related severe side effects, by contrast, were more frequent in the standard group, which received more post-operative drug cycles. Neither group experienced a death within 30 days of surgery.
Quality of life assessments using standard cancer instruments showed no significant differences between the arms in overall health status, physical function, or symptom burden. There were numerical trends favoring the delayed surgery group in social functioning, sexuality, and insomnia, but these did not reach statistical significance and may reflect chance variation.
The researchers acknowledged a key limitation: the trial was designed assuming the standard three-cycle surgery group would achieve a median disease-free survival of 10 months. In reality, these women survived a median of 20.2 months—roughly double the expectation. This better-than-expected outcome in the control arm likely meant the study was underpowered to detect a difference, even if one existed. The trial enrolled 209 patients across multiple centers in an open-label design, meaning both patients and clinicians knew which treatment each woman received.
The findings leave an open question: which patients, if any, might still benefit from extended neoadjuvant chemotherapy? The researchers called for future studies that could stratify women based on tumor biology and chemosensitivity—essentially, identifying a subgroup whose cancers respond particularly well to prolonged drug exposure before surgery. For now, the evidence suggests that the standard approach of operating after three chemotherapy cycles remains the safer choice for most women with advanced ovarian cancer who are not candidates for upfront surgery.
Notable Quotes
The CHRONO trial did not report any superiority of surgery after 6 cycles of NACT compared with surgery after 3 cycles, in terms of disease-free survival, time to subsequent treatment, overall survival, postoperative mortality, severe morbidity, or quality of life.— Jean-Marc Classe, MD, lead study author, Institut de Cancérologie de l'Ouest
The Hearth Conversation Another angle on the story
Why would anyone have thought six cycles of chemotherapy before surgery would be better than three?
The idea was that more chemotherapy would shrink the tumor more completely, making it easier for surgeons to remove all visible disease. And in fact, they did achieve complete removal more often in the delayed group—90 percent versus 83 percent.
But that didn't help them live longer?
No. The disease-free survival was nearly identical between the groups. The extra chemotherapy didn't translate into any survival advantage, despite the better surgical outcomes.
Did the women who waited longer experience more side effects?
Yes. Severe complications within 30 days of surgery were more than twice as common in the delayed group—11 percent versus 5 percent. Though the chemotherapy-related toxicity was actually worse in the standard group, which had more post-operative drug cycles.
So they endured more chemotherapy and more surgery complications for no benefit?
Essentially, yes. And the researchers think the study may not have even been powerful enough to detect a real difference, because the control group did better than expected. But based on what they found, waiting longer doesn't help most patients.
What happens next?
They're calling for studies that look at individual tumor biology—trying to identify which patients, if any, might actually benefit from the extended approach. For now, the standard three-cycle approach appears to be the right choice.